Loading...
Loading...
Jefferies and Company is out with a research report this morning, where it reiterates its Buy rating on Auxilium Pharma
AUXL; it has a price target of $42.00 on the stock.
The Jefferies analysts cited the fact that AUXL recently announced that the US Patent and Trademark Office has issued a new patent for Xiaflex, claiming a 1:1 ratio of collagenase 1 vs. 2 in the Xiaflex formulation with over 97% purity.
The analysts are estimating that extending Xiaflex market exclusivity from 2022 to 2028 could add at least $6/share to the valuation.
As for valuation, they remarked, “We maintain our 12-month price target of $42, based on 15x 2015 EPS, discounted 20%. This multiple is near the bottom of our mid-cap range. AUXL is subject to clinical, regulatory, and reimbursement risks.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in